Anakinra treats fulminant myocarditis from
Anakinra
Case report
Myocarditis
Neisseria meningitidis
Sepsis
Journal
European heart journal. Case reports
ISSN: 2514-2119
Titre abrégé: Eur Heart J Case Rep
Pays: England
ID NLM: 101730741
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
02
02
2021
revised:
22
03
2021
accepted:
30
04
2021
entrez:
18
6
2021
pubmed:
19
6
2021
medline:
19
6
2021
Statut:
epublish
Résumé
Fulminant myocarditis is a life-threatening condition characterized by acute cardiac dysfunction requiring pharmacological or mechanical circulatory support. Haemophagocytic lymphohistiocytosis (HLH) is an uncommon state of immune dysregulation and overactivation. Inflammation mediated by interleukin-1 (IL-1) is thought to play a role in the pathogenesis of myocarditis and HLH, and there is some evidence that the IL-1 receptor antagonist Anakinra may play a role in treating both these conditions. A 26-year-old previously healthy male presented to the Emergency Department with a 3-day history of malaise, headache, vomiting, diarrhoea, and fever. He was profoundly hypotensive on arrival, diagnosed with septic shock, and commenced on broad-spectrum antibiotics and vasopressors. Blood tests showed lymphopenia, thrombocytopenia, low fibrinogen and elevated high sensitivity troponin T, ferritin, and C-reactive protein. Echocardiography demonstrated severely impaired biventricular systolic function and a diagnosis of fulminant myocarditis was made. His condition deteriorated and he required intubation and additional inotropic support. A diagnosis of HLH was made and he was commenced on Anakinra and Methylprednisolone. His condition improved rapidly thereafter. Polymerase chain reaction testing subsequently confirmed infection with In this case, fulminant myocarditis and HLH were life-threatening manifestations of meningococcal septicaemia, and the patient's condition improved rapidly following administration of the IL-1 receptor antagonist Anakinra. These complications should be borne in mind in septic patients with marked haemodynamic instability and multiorgan dysfunction, and treatment with Anakinra should be considered in those who fail to respond to conventional therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Fulminant myocarditis is a life-threatening condition characterized by acute cardiac dysfunction requiring pharmacological or mechanical circulatory support. Haemophagocytic lymphohistiocytosis (HLH) is an uncommon state of immune dysregulation and overactivation. Inflammation mediated by interleukin-1 (IL-1) is thought to play a role in the pathogenesis of myocarditis and HLH, and there is some evidence that the IL-1 receptor antagonist Anakinra may play a role in treating both these conditions.
CASE SUMMARY
METHODS
A 26-year-old previously healthy male presented to the Emergency Department with a 3-day history of malaise, headache, vomiting, diarrhoea, and fever. He was profoundly hypotensive on arrival, diagnosed with septic shock, and commenced on broad-spectrum antibiotics and vasopressors. Blood tests showed lymphopenia, thrombocytopenia, low fibrinogen and elevated high sensitivity troponin T, ferritin, and C-reactive protein. Echocardiography demonstrated severely impaired biventricular systolic function and a diagnosis of fulminant myocarditis was made. His condition deteriorated and he required intubation and additional inotropic support. A diagnosis of HLH was made and he was commenced on Anakinra and Methylprednisolone. His condition improved rapidly thereafter. Polymerase chain reaction testing subsequently confirmed infection with
DISCUSSION
CONCLUSIONS
In this case, fulminant myocarditis and HLH were life-threatening manifestations of meningococcal septicaemia, and the patient's condition improved rapidly following administration of the IL-1 receptor antagonist Anakinra. These complications should be borne in mind in septic patients with marked haemodynamic instability and multiorgan dysfunction, and treatment with Anakinra should be considered in those who fail to respond to conventional therapy.
Identifiants
pubmed: 34142010
doi: 10.1093/ehjcr/ytab201
pii: ytab201
pmc: PMC8207165
doi:
Types de publication
Case Reports
Langues
eng
Pagination
ytab201Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
J Exp Med. 1996 Mar 1;183(3):949-58
pubmed: 8642298
J Intern Med. 2002 Oct;252(4):283-94
pubmed: 12366601
Rheumatology (Oxford). 2011 Feb;50(2):417-9
pubmed: 20693540
Clin Rheumatol. 2018 Dec;37(12):3329-3335
pubmed: 29663156
Curr Cardiol Rep. 2018 Sep 26;20(11):114
pubmed: 30259175
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Int J Cardiol. 2015;189:220-2
pubmed: 25897909
Eur Heart J. 2009 Aug;30(16):1995-2002
pubmed: 19556262
Nat Clin Pract Cardiovasc Med. 2008 Nov;5(11):693-706
pubmed: 18797433
Front Immunol. 2019 Feb 01;10:119
pubmed: 30774631
Circ Heart Fail. 2017 Nov;10(11):
pubmed: 29141858
Eur Heart J. 2021 Jan 1;42(1):113-131
pubmed: 32176778
Circulation. 1999 Jul 6;100(1):96-102
pubmed: 10393687
Arthritis Rheumatol. 2014 Sep;66(9):2613-20
pubmed: 24782338
PLoS One. 2012;7(3):e33438
pubmed: 22438931